SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
Introduction Globally, individuals with asthma tend to overrely on short-acting β 2-agonists
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma
CS Cabrera, C Nan, N Lindarck… - European …, 2020 - Eur Respiratory Soc
As SABA overuse is associated with exacerbations and mortality, GINA no longer
recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA …
recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA …
[HTML][HTML] Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA …
Background Overuse of short-acting β 2-agonists (SABA) may indicate poor asthma control
and adverse health outcomes. Contemporary population-based data on use, risk factors and …
and adverse health outcomes. Contemporary population-based data on use, risk factors and …
Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program
CI Bloom, C Cabrera, S Arnetorp, K Coulton, C Nan… - Advances in …, 2020 - Springer
Introduction Patients with asthma typically increase short-acting β 2-agonists (SABA) use
with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse …
with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse …
Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
ED Bateman, DB Price, HC Wang… - European …, 2022 - Eur Respiratory Soc
Background To gain a global perspective on short-acting β2-agonist (SABA) prescriptions
and associated asthma-related clinical outcomes in patients with asthma, we assessed …
and associated asthma-related clinical outcomes in patients with asthma, we assessed …
[HTML][HTML] Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America
Background Expert national/global asthma management recommendations raise the issue
whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant …
whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant …
Effective asthma management: is it time to let the AIR out of SABA?
A Kaplan, PD Mitchell, AJ Cave, R Gagnon… - Journal of Clinical …, 2020 - mdpi.com
For years, standard asthma treatment has included short acting beta agonists (SABA),
including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for …
including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for …
[HTML][HTML] The impact of inappropriate use of short acting beta agonists in asthma
Background Inappropriate use of short-acting beta-agonists (SABA) has been associated
with increased morbidity and mortality in asthma. However, the extent and pattern of SABA …
with increased morbidity and mortality in asthma. However, the extent and pattern of SABA …
Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review
Despite the availability of effective asthma treatments, some patients are poorly controlled
because of overreliance on short-acting β 2-agonists (SABAs) and underuse of inhaled …
because of overreliance on short-acting β 2-agonists (SABAs) and underuse of inhaled …
It is time to change the way we manage mild asthma: an update in GINA 2019
Asthma is a heterogeneous lung disease, usually characterised by chronic airway
inflammation. Although evidence-based treatments are available in most countries, asthma …
inflammation. Although evidence-based treatments are available in most countries, asthma …